News | June 02, 2014

CivaTech Oncology’s Linear Brachytherapy Device Added to AAPM Source Registry

June 2, 2014 — CivaTech Oncology’s flagship product, the CivaString source, has been listed on the Joint American Association of Physicists in Medicine/IROC Houston Registry of Brachytherapy Sources meeting the AAPM Dosimetric Prerequisites. This approval is granted through independent investigations and a thorough review process, affirming the robust dosimetric qualities of CivaString and allowing routine product use without special approvals or IRB clinical trial oversight.

This new method of polymer encapsulation of Palladium 103, a low dose rate source with a half–life of 17 days, enables a linear, homogenous dose profile which is designed to be superior to other products encapsulated in metals. CivaString is currently in use for the treatment of prostate cancer.

Suzanne Babcock, CivaTech Oncology chairman and CEO, said, “We are excited to see that both research and clinical usage suggest potential savings of up to 40 percent fewer needles than traditionally required for seed implants. This can result in reductions in tissue trauma and procedural time.” Other advantages of polymer-based brachytherapy include improvement to image quality, should patients require future diagnostics in the region.

The American Cancer Society estimates that in 2014, 233,000 new cases of prostate cancer will be diagnosed and 29,480 men will die of the disease. It is the second leading cause of cancer death among men in the United States. Most men are concerned about the undesirable side effects that accompany all methods of treating prostate cancer and the polymer-based technology may reduce some of these issues.

For more information:

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init